Drug withdrawals from the Canadian market for safety reasons, 1963-2004
- PMID: 15767610
- PMCID: PMC552890
- DOI: 10.1503/cmaj.045021
Drug withdrawals from the Canadian market for safety reasons, 1963-2004
References
-
- KPMG Consulting LP. Review of the Therapeutic Products Programme cost recovery initiative. Ottawa: Ministry of Health; 2000.
-
- Canada's Research-Based Pharmaceutical Companies. Improving health through innovation: a new deal for Canadians [press release]. Ottawa; September 2002.
-
- Office of Inspector General. FDA's review process for new drug applications: a management review. Washington: Department of Health and Human Services; March 2003.
-
- Abraham J, Davis C. Mapping the social and political dynamics of drug safety withdrawals in the UK and the US. Sussex: Economic and Social Research Council; 2002 .
-
- Lurie P, Wolfe SM. FDA medical officers report lower standards permit dangerous drug approvals. Washington: Public Citizen; 1998.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical